Global Cord Blood Mergers & Acquisitions

Global Cord Blood M&A Summary

Global Cord Blood has acquired 2 companies, including 1 in the last 5 years.

Global Cord Blood’s largest acquisition to date was in 2022, when it acquired Cellenkos for $664M. Global Cord Blood has acquired in 1 US state, and 2 countries. The Company’s most targeted sectors include healthcare services (50%) and life science (50%).

M&A Summary

  • M&A Total Activity2
    • M&A Buy Activity2
  • Total Sectors Invested 2
  • Total Countries Invested 2

Global Cord Blood

Global Cord Blood Corp.

Bank of China Tower 48th Floor 1 Garden Road Central,
Hong Kong,
China,
+852 3605 8180
www.globalcordbloodcorp.com

All (2) Buy (2) Sell (-)
Date Target Value
$mlns
Transaction Type Acquirer Seller SRC
Link
2022-04-29 Cellenkos · Life Science
Houston, Texas · www.cellenkosinc.com

Cellenkos is a clinical-stage biotechnology company focused on the development and commercialization of Allogeneic, Tissue-Targeted, Immune T-Regulatory Cell Therapies to Treat Autoimmune Diseases and Inflammatory Disorders. Being derived from umbilical CB. Cellenkos' Tregs are naïve, bonafide suppressor cells that resolve inflammation through multiple direct and indirect interactions. The company utilizes its proprietary CRANETM platform technology to isolate, activate, enrich and expand the tissue-directed CB Treg cells that leverage cellular intelligence to seek, localize, proliferate and resolve tissue inflammation. Cellenkos' in-house cGMP facility allows for large-scale manufacturing where multiple doses can be generated from a single CB unit. These off-the-shelf allogeneic cell products are cryopreserved and are available on-demand for infusion at the point of care. Cellenkos is based in Houston, Texas.

664 Add-on Acquisition

Global Cord Blood

-

Try Mergr Free — See This and 220,453+
Other Company and Investor Profiles Today

Try free. Full access. Cancel anytime.

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.

We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore an investment firm’s investment criteria, deal history, portfolio, and connections - organized to help you uncover opportunities and make informed decisions.

With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.8K Private Equity Firms
  • 214K M&A Transactions
  • 216K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.8K M&A Advisors
    (Investment Banks and Law Firms)
  • 82K M&A Contacts
    (PE and M&A Advisors)

What next?

Try Free

Full access to Mergr's investor, acquirer, and transaction data starts here.